{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:01:26Z","timestamp":1790182886394,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,4]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Soft tissue sarcomas (STS) are rare malignant tumours typically treated with surgery in combination with radiotherapy and\/or chemotherapy. Conventional preoperative radiotherapy (25\u00d72\u2009Gy) prolongs treatment duration up to 3\u20135 months, which can substantially have an impact on the patient\u2019s burden. Moderate hypofractionated schedules (14\u201315\u00d72.85\u20133\u2009Gy) have shown comparable oncological outcomes and toxicity profiles to conventional treatment. Data on ultra-hypofractionated regimens, such as 5\u00d76\u2009Gy, suggest comparable outcomes. The SCOPES-II trial is designed to evaluate and compare a moderately hypofractionated radiotherapy regimen (14\u00d73\u2009Gy) with an ultra-hypofractionated schedule (5\u00d76\u2009Gy) in adults diagnosed with STS of intermediate or high histological grade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This international, multicentre, randomised phase II trial will include 150 adult patients with localised STS showing intermediate or high tumour grade, arising in the head and neck region, trunk, chest wall or limbs. Patients assigned to arm A will receive preoperative radiotherapy delivered as 14 fractions of 3\u2009Gy, whereas those in arm B will undergo treatment consisting of 5 fractions of 6\u2009Gy. In both treatment arms, surgical resection is planned approximately 6 to 8 weeks following completion of radiotherapy. The primary endpoint is the rate of postoperative wound-related complications occurring within 120 days after surgery. Secondary objectives comprise assessment of oncological efficacy, including local control and the development of distant disease, evaluation of late radiation-associated toxicities, patient-reported Health-Related Quality of Life (HRQoL) and an analysis of cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval for this trial has been obtained from the relevant Medical Ethics Committees (METc) in both the Netherlands (Medisch-Ethische Toetsingscommissie NedMec NL009842) and Poland (43\/2026). Written informed consent will be obtained from all participants before inclusion in the study. The findings of this trial will be shared through publication in international peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT07071727\">NCT07071727<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117842","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:25Z","timestamp":1790179825000},"page":"e117842","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["SCOPES-II: short course of preoperative radiotherapy in head and neck, trunk and extremity soft tissue sarcomas \u2013 study protocol for a second randomised phase II clinical trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07071727","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03819985","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04562480","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04425967","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07071727","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5445-4120","authenticated-orcid":false,"given":"Geraldien Florine","family":"Foppele","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fiocco","sequence":"additional","affiliation":[{"name":"Mathematical Institute, Leiden University, Leiden, The Netherlands"},{"name":"Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Princess M\u00e1xima Centre for Paediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Husson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Department of Public Health & Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Kramer","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P","family":"Ret\u00e8l","sequence":"additional","affiliation":[{"name":"Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[{"name":"Department of Biometrics, the Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith V","family":"Bovee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands"},{"name":"Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1767-1796","authenticated-orcid":false,"given":"Gerry","family":"Feeney","sequence":"additional","affiliation":[{"name":"Patient advocate, Sarcoma Patients Advocacy Global Network, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred J F","family":"Ubbels","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e8tra M","family":"Braam","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0326-7345","authenticated-orcid":false,"given":"Brian","family":"Balgobind","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Vries","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Erasmus MC Cancer Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik W","family":"Wesseling","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy (Maastro), Maastricht University Medical Centre+, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"},{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Spalek","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"},{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick L","family":"Haas","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette M","family":"Wiltink","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092309101515000_16.9.e117842.1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O\u2019Sullivan","year":"2002","journal-title":"The Lancet"},{"key":"2026092309101515000_16.9.e117842.2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1667\/RADE-20-00226.1","article-title":"Cellular Radiosensitivity of Soft Tissue Sarcoma","volume":"196","author":"Haas","year":"2021","journal-title":"Radiat Res"},{"key":"2026092309101515000_16.9.e117842.3","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35542","article-title":"Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes","volume":"131","author":"Bishop","year":"2025","journal-title":"Cancer"},{"key":"2026092309101515000_16.9.e117842.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00638-6"},{"key":"2026092309101515000_16.9.e117842.5","doi-asserted-by":"crossref","first-page":"115234","DOI":"10.1016\/j.ejca.2025.115234","article-title":"Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas","volume":"217","author":"Foppele","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026092309101515000_16.9.e117842.6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijrobp.2025.05.006","article-title":"Hypofractionated Preoperative Radiation Therapy for Extremity and Superficial Trunk Soft Tissue Sarcomas: Results of a Prospective, Phase 2 Trial","volume":"123","author":"Ahmed","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092309101515000_16.9.e117842.7","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.esmorc.2025.100029","article-title":"SCOPES: short course of preoperative radiotherapy in head and neck, trunk and extremity soft tissue sarcomas\u2014a randomized phase II clinical trial","volume":"4","author":"Foppele","year":"2025","journal-title":"ESMO Rare Cancers"},{"key":"2026092309101515000_16.9.e117842.8","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.24.00238","article-title":"Hypofractionated Preoperative Radiation Should Not Yet Be Used as Standard of Care for Extremity and Truncal Soft Tissue Sarcoma","volume":"42","author":"Baldini","year":"2024","journal-title":"JCO"},{"key":"2026092309101515000_16.9.e117842.9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.ejso.2014.05.016","article-title":"Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas","volume":"40","author":"Kose\u0142a-Paterczyk","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2026092309101515000_16.9.e117842.10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122981","article-title":"Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk Wall","volume":"13","author":"Kose\u0142a-Paterczyk","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092309101515000_16.9.e117842.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.adro.2021.100850","article-title":"Is 5 the New 25? Long-Term Oncologic Outcomes From a Phase II, Prospective, 5-Fraction Preoperative Radiation Therapy Trial in Patients With Localized Soft Tissue Sarcoma","volume":"7","author":"Bedi","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"2026092309101515000_16.9.e117842.12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2021.06.027","article-title":"Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities","volume":"161","author":"Leite","year":"2021","journal-title":"Radiother Oncol"},{"key":"2026092309101515000_16.9.e117842.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3524"},{"key":"2026092309101515000_16.9.e117842.14","unstructured":"Terminology criteria for adverse events (CTCAE) version 5.0. 2017."},{"key":"2026092309101515000_16.9.e117842.15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2340\/1651-226X.2025.43110","article-title":"Development and the need for implementation of a health-related quality of life measurement strategy for patients with soft tissue sarcoma undergoing preoperative radiotherapy","volume":"64","author":"Foppele","year":"2025","journal-title":"Acta Oncol"},{"key":"2026092309101515000_16.9.e117842.16","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2026092309101515000_16.9.e117842.17","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"2026092309101515000_16.9.e117842.18","unstructured":"Blackwelder WC . Equivalence trials. New York: John Wiley and Sons, 1998:1367\u201372."},{"key":"2026092309101515000_16.9.e117842.19","unstructured":"Shein-Chung C , Jun S , Hansheng W . Sample size calculations in clinical research. New York: Marcel Dekker, 2003."},{"key":"2026092309101515000_16.9.e117842.20","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712"},{"key":"2026092309101515000_16.9.e117842.21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statist"},{"key":"2026092309101515000_16.9.e117842.22","doi-asserted-by":"crossref","unstructured":"Briggs A , Sculpher M , Claxton K . Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"2026092309101515000_16.9.e117842.23","unstructured":"Hakkaart - van Roijen L , Peeters S , Kanters T , et al . Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen. Erasmus Universiteit Rotterdam, 2024."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:32Z","timestamp":1790179832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-117842"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117842","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}